Document is current
Any future updates will be listed below
-
Authors
Roshal, Mikhail
Kong, Isabella Y.
Dinalankara, Wikum
Reichel, Jonathan B.
Teater, Matthew
Binder, Bhavneet
Zairis, Sakellarios
Brody, Joshua D.
Park, Sunita I.
Kovach, Alexandra E.
Gulati, Nitya
Oberley, Matthew J.
Lim, Megan S.
Barth, Matthew J.
Elemento, Olivier https://orcid.org/0000-0002-8061-9617
Melnick, Ari https://orcid.org/0000-0002-8074-2287
Rabadan, Raul
Chadburn, Amy
Marchionni, Luigi
Giulino-Roth, Lisa
Cesarman, Ethel https://orcid.org/0000-0003-3303-6299
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA068939)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (5T32GM083937)
- License Information
-
More Information
Article History
Received: 26 October 2025
Revised: 10 March 2026
Accepted: 31 March 2026
First Online: 22 April 2026
Competing interests
: We have the following relationships to disclose, none of which are related to the current study. Matthew J. Oberley has equity in Caris Life Sciences. Lisa Giulino-Roth is a consultant for Pierre Fabre, Bristol Myers Squibb, Roche, Merck (paid to institution). She has received research support from Ipsen and Roche. Ethel Cesarman is a consultant for Sanofi.
